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1. SUMMARY  
Atrial fibrillation (AF) is the most common clinical tachyarrhythmia and is expected to 
affect about 30 million North Americans and Europeans by 2050.1 It is widely 
acknowledged that one of the main features of AF is its progressive nature, which hampers 
the effective functional conversion to sinus rhythm in patients with persistent forms of 
AF.2-4 This progressive nature and impaired functional recovery are rooted in AF-induced 
irreversible cardiomyocyte remodeling, especially structural remodeling, which promotes 
the persistence of AF.4-7 Current AF drug therapies target the reversible electrical changes 
and therefore have limited effect on patients’ outcome.8 A balanced eukaryotic protein 
homeostasis, i.e. a proper proteostasis, enables healthy cell and organismal development 
and protects against diseases.9 Recently, our lab revealed evidence that derailment of 
proteostasis is a main contributor to the development of structural remodeling in AF and 
underlies AF progression. In addition, HSP-inducing compounds are promising 
therapeutics to prevent AF progression by preserving proteostasis, which is reviewed in 
chapter 2.7,10-12 Besides HSPs, many other modifiers, including HDACs and autophagy, 
influence proteostasis.9 However, the detailed molecular pathways contributing to 
derailment of proteostasis in AF remain unidentified. Therefore, the main goal of this thesis 
is to elucidate if key modulators of proteostasis get derailed in AF and whether these key 
modulators represent druggable targets to attenuate AF initiation and progression.   
1.1.  Identify key modulators involved in derailment of proteostasis in AF 
To identify key modulators involved in the derailment of proteostasis in AF, we first 
developed a Drosophila model for AF to screen for compounds that prevent AF 
progression, as described in chapter 3. Tachypaced Drosophila revealed characteristics of 
AF-induced alterations in experimental animal and cardiomyocyte models and in clinical 
AF, including increased arrhythmicity, hypocontractility of the heart wall, activation of 
calpain, myolysis and damaged mitochondria.13 We previously found cardioprotective 
effects by HSP overexpression, especially the small HSPB1, and the HSP-inducing 
compound GGA, against important features of tachycardia remodeling, such as electrical 
and structural remodeling and contractile dysfunction.14-17  In this chapter, we demonstrated 
for the first time, that such protective effects are also observed in the Drosophila model for 
tachypacing-induced contractile dysfunction of the heart wall. We observed that HSP-
inducing agents (GGA and BGP-15), a heat shock pretreatment and overexpression of one 
small HSP, dmHSP23, protect against tachypacing-induced contractile dysfunction. Our 
results show that findings in Drosophila match those of in vitro tachypaced HL-1 and dog 
atrial cardiomyocytes, and therefore the Drosophila model can be used to study tachycardia 
remodeling. Since Drosophila’s gene expression can be easily manipulated in a highly 





























precise spatial and temporal fashion, this model seems to represent an excellent tool to 
study molecular mechanism underlying tachycardia remodeling and AF progression. 
Combined with short life-cycle of Drosophila, cost efficiency and the powerful techniques 
for genetic and molecular manipulations, the Drosophila model is also highly suitable for 
(high-throughput) compound screening.18 
The newly developed Drosophila model and previously developed HL-1 
cardiomyocyte model for AF, were both utilized to screen broad HDAC inhibitors, 
including Trichostatin A (TSA), sodium butyrate (SoBu), nicotinamide, and the specific 
HDAC6 inhibitor tubacin, as described in chapter 4. In this chapter we observed 
nicotinamide and tubacin to protect against contractile dysfunction in both experimental 
models. As tubacin is a specific inhibitor of HDAC6 and nicotinamide can inhibit Class III 
HDACs, sirtuins, we further focused on the role of HDAC6 and sirtuins in AF progression. 
We identified HDAC6 as a key enzyme in the development of a substrate for AF 
progression. Tachypacing of HL-1 cardiomyocytes increased HDAC6 activity and 
expression, resulting in TDAC-domain dependent deacetylation/depolymerization and 
calpain-mediated degradation of α-tubulin with subsequent disruption of the microtubule 
network. HDAC6 inhibition by tubacin conserved the microtubule structure and prevented 
depolymerized α-tubulin from degradation by calpain. Ultimately, this derailment of α-
tubulin proteostasis causes contractile dysfunction. Consistent with our experimental data, 
patients with permanent AF show increased HDAC6 TDAC domain activity and 
expression, and increased deacetylation and degradation of α-tubulin. In these patients the 
amount of α-tubulin degradation correlates with calpain activity. Finally, we obtained proof 
of concept for HDAC6 as a therapeutic target by testing the HDAC6 inhibitor tubastatin A 
in a dog model of AF. Tubastatin A protected against tachypacing-induced electrical and 
structural remodeling and AF progression in dogs. Together, our results identify inhibition 
of HDAC6 as a promising therapeutic target to conserve α-tubulin proteostasis and 
attenuate cardiomyocyte remodeling in AF. 
In addition to HDAC6 inhibitors, we also found that the class III HDAC (sirtuins) 
inhibitor, nicotinamide, protects cardiomyocytes and Drosophila from tachypacing-induced 
remodeling, as described in chapter 4. It is conceivable that inhibition of deacetylation of α-
tubulin also underlies the protective effect of nicotinamide, since HDAC6 and sirtuin both 
deacetylate α-tubulin. However, in contrast to previous reports19, nicotinamide did not 
prevent deacetylation and depolymerization of α-tubulin.20 This observation suggests that 
other mechanism(s) convey the protective effect of nicotinamide in AF, such as increased 
availability of NAD+ by the inhibition of poly(ADP-ribose) polymerases (PARPs).21,22 In 
chapter 5, we describe that nicotinamide inhibits PARP but not sirtuins. In addition, we 
found that AF induces DNA damage and subsequent PARP1 activation. Active PARP1, in 
turn, consumes NAD+, resulting in metabolic remodeling and functional loss in tachypaced 
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cardiomyocytes and Drosophila. Accordingly, replenishment of NAD+ protects against 
tachypacing-induced contractile dysfunction in cardiomyocytes and Drosophila.  Moreover, 
inhibition of PARP, by another broad PARP inhibitor 3-AB or the specific PARP1/2 
inhibitor ABT-888, protects against tachypacing-induced contractile dysfunction in HL-1 
cardiomyocytes and Drosophila. Consistent with these findings, PARP is also activated in 
atrial tachypaced dogs and permanent AF patients, and PARP activation correlates with the 
level of DNA damage. Taken together, these findings suggest a dominant role of PARP1 in 
AF-induced metabolic and functional remodeling and consequently disease progression. 
Having identified the role of class IIb member HDAC6 in AF in chapter 4, we 
continued exploring the role of class I and class IIa HDACs in tachypacing-induced 
cardiomyocyte remodeling in chapter 6. We found that class I HDAC1 and HDAC3 
overexpression have detrimental effects on contractile function in tachypaced HL-1 
cardiomyocytes. In contrast, overexpression of class IIa HDAC5 and HDAC7 revealed 
protective effects. Their protective effects were suppressed in cardiomyocytes 
overexpressing HDAC5 or HDAC7 with a mutation in the binding domain for MEF2, 
revealing MEF2 as a downstream effector of HDAC5 and HDAC7. Moreover, tachypacing 
induced HDAC5 phosphorylation, nuclear export and downstream fetal gene activation 
(BNP, β-MHC) in HL-1 cardiomyocytes. Similar results were observed in permanent AF 
patients, suggesting a role for HDAC5 in the progression of clinical AF. 
Recently, HDAC inhibitors have been found to attenuate cardiac hypertrophy by 
suppressing autophagy.23 In addition, HDAC6 and microtubules are required for proper 
degradation of misfolded proteins in cells via selective autophagy.24-27 Since the 
microtubule network is disrupted due to HDAC6 activation in AF 20, one could speculate 
that autophagy is also dysregulated in AF. Therefore, in chapter 7, we studied the role of 
autophagy in AF. Indeed, we found tachypacing of cardiomyocytes to induce excessive 
autophagy through activation of ER stress signaling in experimental model systems for AF 
as well as in clinical AF. Conservation of cardiac proteostasis was achieved by inhibition of 
ER stress-induced autophagy with the chemical chaperone, 4-PBA, as well as with 
overexpression of ER chaperone, HSPA5, thus limiting AF progression. These findings 
suggest that rather than inhibition of autophagy, the inhibition of ER stress  by compounds 
stimulating the expression of ER chaperones, may represent  the preferred novel therapeutic 
intervention strategy for targeting excess autophagy in AF.  
In summary, we identified several key modulators in the derailment of proteostasis to 
contribute to structural remodeling and hence AF progression. HDAC6, class I HDACs 
(HDAC1 and HDAC3), class IIa HDACs (HDAC5 and HDAC7) and ER stress-induced 
autophagy contribute directly to derailment of proteostasis by inducing disruption of 
microtubules, pathological fetal gene expression and myolysis, respectively. Moreover, 
maintaining proteostasis is an ATP dependent process in cells.28 PARP1 activation resulted 





























in depletion of NAD+ levels, which is a coenzyme in ATP production. Therefore, PARP1 
activation contributes to derailment of proteostasis via impairment of ATP production. An 
overview of AF-induced derailment of proteostasis and druggable targets is depicted in 
Figure 1. 
 
Figure 1:   An overview of AF-induced derailment of proteostasis and druggable targets.  AF induces time-
related progressive cardiomyocyte remodeling. First, AF causes cellular Ca2+ overload and oxidative stress, which 
results in a direct inhibition of the L-type Ca2+ channel, shortening of action potential duration and contractile 
dysfunction. These changes have an early onset and are reversible. The early processes protect the cardiomyocyte 
against Ca2+ overload but at the expense of creating a substrate for persistent AF. When AF persists, derailment of 
proteostasis continues, including myolysis by calpain and autophagy, pathological gene expression by HDACs 
(HDAC1, HDAC 3, HDAC5 and HDAC 7), disruption of microtubules by HDAC6, and depletion of NAD+ by 
PARP1 activation and consequent exhaustion of ATP. Derailment of proteostasis results in irreversible alterations 
in structural proteins, thereby creating substrates for impaired contractile function and AF persistence. Novel 
druggable targets include inhibitors of ER stress-induced autophagy, HDAC5-MEF stabilizers, HDAC6 inhibitors, 
PARP1 inhibitors, and NAD supplements, which are listed in Table 1.   
1.2.  novel therapeutic options in AF 
AF-induced remodeling contributes to AF progression and hampers the effective 
treatment of patients. As a result, there is an urgent need for new therapies that slow, arrest 
or even reverse the pathologic changes that occur with AF. The efficacy of drugs presently 
used in AF is limited.1,8 Thus, pharmacological approaches preventing or limiting the 
substrate for the promotion of AF (“upstream therapy”) are warranted.1,8 There are strong 
indications that loss of proteostatic control in cardiomyocytes represents an important 
substrate for the development and progression of AF.10,29 We previously discovered HSP 
inducers to attenuate AF-induced remodeling and can therefore serve as novel therapeutic 
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options in AF29,   which is further confirmed in a newly-developed Drosophila model 
system (chapter 3).13 Beside HSP inducers, we identified several novel therapeutic options 
in AF, which are discussed below (Table 1). 
 
Table 1: Drugs with potential benefit in preventing AF substrate formation currently developed for human 
application. 














Diabetes Mellitus NCT01069965 
NYK9354 HSP induction Pre-clinical Atrial Fibrillation 29 
Tubastatin A HDAC6 Pre-clinical Arthritis 47 
ABT-888 PARP1 inhibitor 
 (Ki = 5.2 nM)   
PARP2 inhibitor 







metastatic breast cancer 
Hepatocellular Carcinoma 




































(IC50 = 5 nM) 
PARP2 inhibitor  
(IC50 = 1 nM)  
Tankyrase 1 
inhibitor 






Advanced Solid Malignancies 
Platin-sensitive ovarian 
cancer 






BSI-201 PARPs Phase III 
Phase II 
Breast Cancer  
Ovarian Cancer 
Advanced Solid Tumors 
NCT00938652 
NCT01033123 
MK-4827 PARP1 inhibitor 
(IC50 = 3.2 nM)  
PARP2 inhibitor 
(IC50 = 4 nM)  
Phase I 
 
Solid tumours and ovarian 
cancer 
NCT01294735 













NAD precursor Phase 0 
Phase 1 



















Maple Syrup Urine Disease 
Diabetes 






































HDAC6 inhibition, by tubacin, conserves α-tubulin proteostasis, prevents its 
degradation by calpain 1 and protects against loss of calcium transient and cardiac 
remodeling in experimental model systems for AF (chapter 4). However, tubacin is not 
suitable for in vivo studies as it has low druglikeness.30 Other HDAC6 inhibitors, such as 
tubastatin A and ACY-1215 have been developed, and show beneficial effects in mice 
models for neurodegenerative diseases and cancer.30-32  We very recently provided the first 
evidence for the efficacy of HDAC6 inhibitors in the dog model for AF.20 Dogs treated 
with tubastatin A were protected against atrial tachypacing-induced electrical remodeling, 
cellular Ca2+ handling/contractile dysfunction and AF progression. These in vivo findings 
strengthen the notion that HDAC6 inhibitors represent a novel therapeutic approach in AF. 
PARP inhibitors and NAD+ supplementation 
The inhibition of PARP proteins has become a promising therapeutic approach in 
several human diseases, including cardiovascular diseases.22 In chapter 5, we identified 
PARP1 activation in experimental models and in human permanent AF, and demonstrate 
the protective effect of ABT-888 in HL-1 cardiomyocytes and Drosophila. Recently, novel 
PARP inhibitors have entered clinical development for various cardiovascular 
indications.33,34 Early PARP inhibitors, such as 3-AB and nicotinamide, are designed to 
compete with NAD+ at the active site of the enzyme. They have little specificity for 
individual PARP proteins, with half-maximal inhibitory concentration (IC50) values in the 
micromolar range, and they elicit significant off-target effects and toxicity.35,36 The newer 
PARP inhibitors exhibit increased potency and specificity, with IC50 values reaching the 
low nanomolar range, and even PARP family member selectivity for some inhibitors. For 
example, ABT888 inhibits only PARP1 and PARP2 with high potency37, and is now in 
phase I and II for clinical cancer studies.34,36 Consequently, our findings call for the 
exploration of the action of ABT-888 in large animal models and in human AF. In addition, 
NAD+ supplementation protects against tachypacing-induced remodeling in HL-1 
cardiomyocytes and Drosophila. Currently, NAD+ precursors, such as niacin and 
nicotinamide riboside, which are currently tested in clinical trials in patients with heart 
diseases and in healthy patients (Table 1), might also represent therapeutic options in AF. 
HDAC5-MEF2 complexes stabilizer 
In chapter 6, we observed a key role for class IIa HDAC5 in AF remodeling via 
suppression of MEF2 activity. So compounds inhibiting the release of HDAC5 from MEF2 
might have a therapeutic potential for treatment of AF and it is of interest to test these 
compounds in experimental and clinical AF. One interesting compound is MC1568, since it 
inhibits the activity of HDAC4 and HDAC5, thereby leaving MEF2-HDAC complexes in a 
repressed state.38 In addition, inhibitors of upstream kinases which phosphorylate HDAC5 
Chapter 8 
 164 
and thus its subsequent nuclear export, would also be of interest. A more upstream 
approach is to inhibit CaMK and PKC, since these represent two main kinases involved in 
HDAC5 phosphorylation and nuclear export in cardiomyocytes.39 In accord, CaMK 
inhibitors have been reported to prevent AF40, while the PKC inhibitor Go6983 blocked 
HDAC5 nuclear export and also α-tubulin deacetylation after nerve injury.41  Given that 
deacetylation of α-tubulin is involved in AF structural remodeling20, PKC inhibitor Go6983 
is also an interesting candidate to test in our experimental model systems. Thus, our study 
suggests that AF induces HDAC5 phosphorylation, leading to derepression of MEF2 
responsive genes, in turn contributing to cardiomyocyte remodeling and AF progression. 
Therefore, a stabilizer of HDAC5-MEF2 complex, which prevents AF-induced HDAC5 
release from MEF2, such as MC1568 and the PKC inhibitor Go6983, might represent novel 
therapeutic approaches to attenuate AF progression. 
ER stress inhibitors  
In chapter 7, we revealed that inhibition of ER-stress induced autophagy preserves 
proteostasis and protects against cardiomyocyte dysfunction in experimental model systems 
for AF. Therefore, pharmacological intervention to inhibit autophagy may constitute a 
promising therapeutic strategy in clinical AF. Currently, autophagy can be modulated by a 
number of small molecules.42 Since basal autophagy is crucial for normal cell physiology, 
chronic treatment with autophagy inhibitors, such as in permanent AF, may be detrimental 
to the cardiomyocyte.43,44 Such view is corroborated by the high toxicity of bafilomycins, 
which precludes its use in the clinical setting.45  As the clinical options for autophagy 
inhibition are currently limited, inhibitors of ER stress may represent a suitable alternative, 
as identified in chapter 7. From the available compounds, the chemical chaperone 4-PBA 
seems the most promising, as this compound not only inhibits ER-stress induced 
autophagy, but also has been approved for clinical use (Table 1). More importantly, 4-PBA 
was reported to have minor side effects and is considered safe in patients.46 Currently, we 
conduct a 4-PBA study in the dog model for AF, in collaboration with Dr. S. Nattel, which 
so far shows encouraging results. Therefore, our findings suggest 4-PBA as a therapeutic 
agent with great potential in clinical AF. 
2. DISCUSSION: key role of HDACs in cardiac proteostasis 
As reviewed in chapter 2, loss of proteostasis creates a substrate for AF initiation and 
progression.10 We previously found HSPs to protect against AF by preserving proteostasis 
in experimental models for AF as well as in clinical AF.14,15,48,49 Here, we identified a group 
of enzymes, HDACs, to be an important modulator of proteostasis in AF (chapter 4 and 
chapter 6).20  HDACs have been recently implicated in various heart diseases, especially 
heart failure. Liu et al. were the first to show that HDAC inhibition reverses atrial 





























arrhythmia inducibility and fibrosis in cardiac hypertrophy.50 We discovered that class I 
HDACs (HDAC1 and HDAC3), class IIa (HDAC5 and HDAC7), and class IIb (HDAC6) 
to be involved in derailment of proteostasis and subsequent tachypacing-induced contractile 
dysfunction and structural remodeling in AF. The potential mechanisms of HDACs to 
regulate proteostasis in heart diseases include by epigenetic regulation, by deacetylation of 
contractile and structural proteins or by modulation of autophagy and/or HSP production 
(Figure 2).  The detailed mechanisms are discussed below.  
 
Figure 2: The role of HDACs in cardiac proteostasis network, regulating cardiac protein function and 
structural remodeling. Shown are the interactions that comprise the cardiac proteostasis network responsible for 
cardiac protein function. Central components of the cardiac proteostasis network are outlined in the inner layer 
(green) including synthesis, folding, post translational modification (PTM) and degradation. The second layer 
(purple) consists of major modifiers of each central component. The specific HDACs regulating each modifier in 
the second layer are indicated in the third layer (yellow). Stress activates these HDACs, thereby contributing to 
derailment of proteostasis, details of which are indicated in the fourth layer (red). 
2.1. Aspects of epigenetic regulation by HDACs: transcriptional reprogramming 
Transcriptional reprogramming, especially by activation of the fetal gene program, is 
associated with AF susceptibility and progression.51,52 For example, the thick filament of 
the mammalian sarcomere consists of two myosin isoforms, fast-contracting alpha-myosin 
heavy chain (α-MHC) and slow-contracting beta-myosin heavy chain (β-MHC). Stress 
signals enhance the expression of fetal β-MHC and reduce the expression of adult α-MHC. 
The consequences include diminished myofibrillar ATPase activity and impaired 
contractility.53 In AF patients, myolytic cardiomyocytes are in a dedifferentiated state 
resembling that of immature muscle cells. Here, β-myosin heavy chain (MHC) and smooth 
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muscle α-actin (α-SMA), two proteins of the fetal program, were re-expressed.54  In both, 
tachypaced HL-1 cardiomyocyte model and  canine model for AF, transcriptional 
expression of α-MHC was decreased.55,56 However, the mechanisms underlying 
transcriptional reprogramming and fetal gene expression in AF is not yet elucidated. 
HDACs can deacetylate histones and numerous transcriptional factors57, thereby 
affecting multiple processes by altering chromatin structure and gene expression. Studies 
on heart failure and development strongly indicate, that class I and IIa HDACs are involved 
in transcriptional (i.e., chromatin-related) reprogramming.58-60 Class IIa HDACs (HDAC4, 
HDAC5, HDAC7, and HDAC9), and especially HDAC4 and HDAC5, are highly expressed 
in the heart. Class IIa HDACs normally repress pathological cardiac fetal gene expression. 
In response to stress signals, class IIa HDACs are phosphorylated and undergo nuclear 
export, resulting in derepression of downstream target pathological fetal genes.60 Generally, 
class IIa HDACs regulate gene expression through recruitment of class I HDACs and 
interaction with various transcription factors. Numerous transcription factors have been 
implicated in stress-dependent gene expression in the heart. Most of these transcription 
factors do not change abundantly in the stressed myocardium, suggesting that their 
enhanced activity depends on posttranslational mechanisms. HATs and HDACs play a 
central role in modulating the activities of these transcription factors during pathological 
cardiac growth and development61, and our findings strongly indicate that HDACs play also 
a key role in AF.  
Table 2: Overview of cardiac transcription factors (TGs) regulated by HDACs 












Cardiac hypertrophy 75,76 
NKX 2.5 HDAC5 Heart development, NCX1 expression 92 




Glucose Homeostasis 94,95 
PGC-1α HDAC5 
SIRT1 





Cardiac infarction 97 
 





























HDACs in cardiac hypertrophy and heart failure 
One transcriptional mechanism by which HDACs regulate the phenotype of the heart, 
involves the hypertrophic transcription factor MEF2.38,62-68 In pathological cardiac 
remodeling, MEF2 may serve as a platform on which HATs and HDACs converge as 
positive and negative regulators of pathologic cardiac gene expression. Despite high levels 
of MEF2 expression in heart, MEF2 induced proteins display only basal levels of 
transcriptional activity in adult myocardium.69 Hypertrophic agonists or biomechanical 
stress result in a dissociation of class IIa HDACs from MEF2, the export of HDACs from 
the nucleus, exchange of HDAC for HAT binding and consequent activation of MEF2 
target genes leading to pathological cardiac growth.70 Another transcription factor regulated 
by HDACs is krüppel-like factor 4 (KLF4). KLF4 overexpression blocks cardiac 
hypertrophy in cultured cells and KLF4 knockout mice develop exaggerated cardiac 
hypertrophy and fibrosis in response to pressure overload.71-73 Pan-HDAC inhibitors 
increase the expression of KLF4 in cultured cardiomyocytes, and the resulting increase in 
KLF4 expression appears to be sufficient to block agonist-dependent hypertrophy of the 
cells.71,72 
In patients with heart failure, reactivation of a fetal gene program, including atrial 
natriuretic peptide (ANP) and brain natriuretic peptide (BNP), is a hallmark for maladaptive 
remodeling of the left ventricle.74 Expression of BNP is enhanced in ventricular 
cardiomyocytes during pathological cardiac hypertrophy, and circulating BNP levels are 
used clinically as a surrogate measure for heart failure. Employing cultured neonatal rat 
cardiac myocytes, Gardner and colleagues demonstrated that upregulation of BNP 
expression in response to endothelin signaling is dependent on association of HDAC2 with 
the Yin Yang 1 (YY1) transcription factor on the BNP gene promoter.75 YY1 is acetylated 
in cardiac myocytes, and deacetylation of this transcription factor by HDAC2 enhances its 
ability to stimulate BNP gene transcription. TSA treatment disrupts YY1-HDAC2 
complexes and suppresses endothelin-induced BNP expression. In addition, the interaction 
of HDAC4 and HDAC5 with YY1 was also found necessary for the repressor activity of 
YY1 in cardiac specific promoters.76 Recently, it was shown that in isolated working 
murine hearts, an acute increase of cardiac preload induced HDAC4 nuclear export, H3K9 
demethylation, HP1 dissociation from the promoter region, and activation of the ANP gene. 
Increased cardiac preload and/or activated CaMKIIδB induces nucleo-cytoplasmic shuttling 
of HDAC4 and dissociation of its corepressor complex with SUV39H1 and HP1. This 
relieves H3K9me3, resulting in chromatin condensation, and repression of ANP and BNP 
gene transcription in response to MEF2.74 Given the apparent role of HDACs in AF, these 
results in heart failure warrant the exploration of the involvement of above mentioned 
transcription factors in AF-induced cardiomyocyte structural and functional remodeling.  
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HDACs in cardiac fibrosis 
An important substrate for AF induction is fibrosis. Interestingly, much of the 
beneficial effects of HDAC inhibitors in models of heart failure are likely due to inhibition 
of pathological fibrosis, although surprisingly little is known about the anti-fibrotic 
mechanisms of HDAC inhibitors in the heart.77 It seems likely that HDAC inhibitors block 
cardiac fibrosis by multiple mechanisms, including inhibition of cardiac fibroblast 
proliferation or migration, induction of genes that suppress extracellular matrix production 
from fibroblasts, suppression of proinflammatory cues for fibrosis, and blockade of the 
endothelial-to-mesenchymal transition (Endo-MT). 
Endo-MT is a form of epithelial-to-mesenchymal transition (EMT) that occurs during 
the embryonic development of the heart: the mesenchymal cells that form the 
atrioventricular cushion, the primordia of the valves and septa of the adult heart, are derived 
from the endocardium by Endo-MT.78 Endo-MT initiates a process of pathological 
dedifferentiation of vascular endothelial cells into matrix-producing mesenchymal cells. 
During this process, excessive numbers of cardiac fibroblasts are produced in adult hearts 
in response to pressure overload 79 and myocardial infarction.80 Cardiac Endo-MT is 
stimulated by Transforming Growth Factor-Beta (TGF-β) and suppressed by Bone 
Morphogenic Protein-7 (BMP-7)79, which blocks fibrosis.81 Endothelin-1, a potent 
vasoconstrictor with promitogenic properties, stimulates cardiac fibrosis by promoting 
Endo-MT.82 TSA blocks EMT, by inhibition of HDAC1 and HDAC2.83 Shan et al. 
investigated the role of HDAC6 in TGF-β1-induced EMT and showed that TGF-β1 induces 
HDAC6-dependent deacetylation of α-tubulin in human lung epithelial cells, which was 
concurrent with the expression of EMT markers. Inhibition of HDAC6 attenuated the TGF-
β1-induced expression of EMT markers as well as activation of SMAD3. In addition, 
inhibition of SMAD3 activation abrogated HDAC6-dependent deacetylation of α-tubulin 
and the expression of EMT markers induced by TGF-β1.84,85 Yu et al. found that high 
concentrations of glucose induced EMT, suggested by a decreased expression of E-cadherin 
and increased expression of α-SMA, fibronectin, and type I collagen and by increased cell 
migration.86  As such, future studies should address whether HDAC inhibition alters Endo-
MT in the heart. Interestingly, these initiators of Endo-MT, such as TGF-β187, fibrosis88, 
HDAC6 activation20and high glucose89 are all related to AF induction and progression. 
Whether Endo-MT occurs in AF and contributes to AF progression remains also to be 
studied. 
HDACs in regulation of ion channels 
NKX2.5 is a transcription factor that regulates cardiac development in humans. 
NKX2.5 works along with MEF2, HAND1, and HAND2 transcription factors to direct 
heart looping during early development. NKX2.5 in vertebrates is equivalent to the 





























‘tinman’ gene in Drosophila and directly activates the MEF2 gene to control 
cardiomyocyte differentiation.90 NKX2.5 operates in a positive feedback loop with GATA 
transcription factors to regulate cardiomyocyte formation.91 NKX2.5 influences HAND1 
and HAND2 transcription factors that control essential asymmetrical development of the 
heart’s ventricles. NKX2.5 recruits HDAC5 to the sodium-calcium exchanger gene (NCX1) 
promoter, where HDAC5 complexes with HDAC1. Chandrasekaran et al. demonstrated 
that acetylation of NKX2.5 induces its association with HDAC5, whereas deacetylated 
NKX2.5 is in a complex with p300. Notably, TSA treatment prevents p300 from being 
recruited to the endogenous NCX1 promoter, resulting in the repression of the NCX1 
gene.92 
2.2. Direct modulation of contractile function by deacetylating structural and contractile 
protein 
HDACs can deacetylate numerous non-histone and structural proteins57, thereby 
affecting multiple processes beyond altering chromatin structure and gene expression.  
Work by Gupta and colleagues revealed that class I HDAC3 localizes to cardiac 
sarcomeres, thereby regulating the cardiac contractility.98 Deacetylation of both α- and β-
MHC by HDAC3 reduces their affinity for actin, resulting in decreased actin sliding 
velocity of the myosin heads.98  
Class IIa HDAC4 is also localized to cardiac sarcomeres, where it appears to decrease 
myofilament calcium sensitivity by promoting deacetylation of muscle LIM protein (MLP). 
It remains unclear whether MLP is a direct substrate of HDAC4.99 Indeed, for many years it 
was believed that class IIa HDACs lacked intrinsic catalytic activity, because recombinant 
forms fail to deacetylate canonical HDAC substrates. Instead, the catalytic activity of class 
IIa HDACs was attributed to their association with class I HDACs.100 However, a synthetic 
substrate that is efficiently deacetylated by class IIa HDACs has been identified recently.101 
Nevertheless, the endogenous substrates of class IIa HDACs in the heart have not been 
identified. Further investigation is needed to address the role of HDAC4 in the control of 
cardiac contractility, as well as the general role of class IIa HDAC catalytic activity in the 
heart.  
Class IIb HDAC6 activation leads to microtubule structure disruption and contractile 
dysfunction.20 Microtubules together with cortical (non-sarcomeric) actin filaments, desmin 
(intermediate) filaments forms the cytoskeleton of cardiomyocytes. Microtubule 
dysregulation has been reported to be involved in various heart diseases.102-105 Microtubules 
are necessary for enhanced gap junction growth and likely facilitate connexin trafficking 
under basal conditions.106 HDAC6 is a key enzyme to deacetylate α-tubulin causing 
microtubule depolymerization and influencing microtubule-dependent cell mobility.102,103 
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In addition to its role in microtubule-dependent cell motility, HDAC6 influences actin-
dependent cell motility by altering the acetylation of cortactin, which in turn changes the F-
actin binding activity of cortactin.107 In accord with a main function of HDAC6 in 
preservation of the cytoskeleton, its deletion in mice dramatically improves myofibril force 
generation without blocking cardiac hypertrophy or fibrosis.108 HDAC6 co-purifies with 
cardiac myofibrils, suggesting a possible role for HDAC6 in the control of sarcomere 
protein acetylation and function.108 Furthermore, various extracellular stress stimuli 
consistently increase HDAC6 activity in myocardium, cultured cardiomyocytes and 
fibroblasts.109 Finally, HDAC6 contributes to pathological responses of heart and skeletal 
muscle to chronic angiotensin II signaling108, substantiating the important role of HDAC6 
in cardiac diseases. 
In summary, a combination of chromatin and non-chromatin substrates for HDACs 
will play key roles in derailment of cardiac proteostasis under stress (Figure 3). 
 
Figure 3: Effects of cardiac stress signals on HDACs in proteostasis regulation. Class IIa HDACs normally 
repress pathological cardiac gene expression. In response to stress signals, kinases, including protein kinase C 
(PKC), protein kinase D (PKD) and calcium/calmodulin-dependent kinase (CaMK), directly phosphorylate class 
IIa HDACs to trigger their nuclear export. Class IIa HDACs undergo nuclear export, resulting in derepression of 
downstream target pathological genes contributing to structural remodeling such as fibrosis and hypertrophy and 
changes of ion channel expression. In the cytoplasm, cardiac stress activates HDAC6, HDAC3 and HDAC4. 
HDAC6 deacetylates substrates such as tubulin and cortactin. During stress, HDAC398, HDAC499 and HDAC6108 
colocalize with sarcomeric proteins and contribute to hypocontractility by deacetylation of sarcomeric and 
cytoskeletal proteins.  
2.3. Involvement of HDACs in major proteostasis pathways 
Role of HDACs in autophagy 





























Autophagy is primarily considered a non-selective degradation process induced by 
starvation. Nutrient-independent basal autophagy, in contrast, imposes intracellular quality 
control by selective disposal of aberrant protein aggregates and damaged organelles. 
Controlled autophagy during (mild) cardiac stress conditions, such as nutrient deprivation, 
brief hypoxia and oxidative stress, supports cardiomyocyte survival. In contrast, excessive 
activation of autophagy causes derailment of cell proteostasis by degradation of essential 
proteins and organelles and thereby triggers autophagic cell death, as found in mitral valve 
regurgitation43,110 and cardiac hypertrophy.111 Recently, autophagy has been identified as an 
obligatory element in pathological cardiac remodeling and point to HDAC1 and HDAC2 as 
required effectors.23 HDAC6 is the first HDAC to be found involved in autophagy and is a 
component of the aggresome.27 HDAC6 has the capacity to bind polyubiquitinated 
misfolded protein cargo to dynein motors for transport to aggresomes. Indeed, cells 
deficient in HDAC6 fail to clear misfolded protein aggregates from the cytoplasm, cannot 
form aggresomes properly, and are hypersensitive to accumulation of misfolded proteins. 
These findings identify HDAC6 as a crucial player in the cellular management of misfolded 
proteins.27 HDAC6 recruits and deacetylates cortactin, thereby promoting F-actin 
remodeling important for autophagosome-lysome fusion and protein aggregate clearance 
and defective mitochondria clearance.24,112 HDAC6 overexpression activates c-Jun NH2-
terminal kinase (JNK) and activates autophagic cell death through the c-Jun NH2-terminal 
kinase (JNK)/Beclin 1 pathway in liver cancer.113 In summary, HDAC1, HDAC2 and 
HDAC6 are involved in the regulation of autophagy, which we demonstrate in chapter 7 to 
be activated by ER-stress in AF. However, to which extend HDACs are involved in the 
regulation of autophagy in AF remains unclear and needs future investigation. 
Role of HDACs in HSP production 
With respect to maintenance of proteostasis in case of protein misfolding, HDACs may 
also have an indirect effect via HSPs, which are known to (re)fold misfolded proteins and 
thereby prevent proteotoxic effects in the cell. Reports about the role of HDACs in the 
regulation HSP production are limited and reveal seemingly conflicting conclusions among 
different HDAC classes. 
Inhibitors of class I/II HDACs have been reported to boost HSP production in various 
cells, suggesting that protective effects of these inhibitors may be related to HSP 
expression. In mouse and human embryonic stem (ES) cells, class I/II HDAC inhibitors, 
TSA, SoBu, suberoylanilide hydroxamic acid (SAHA) and valproic acid trigger early 
differentiation of mouse ES cells and induction of HSP70. In contrast, a class III HDAC 
inhibitor, nicotinamide, fails to induce HSP70 expression or differentiation in these ES 
cells.114 TSA but not nicotinamide induces an association of HSF1 with the HSP70 
promoter, indicating that HSF1 is activated and bind to the HSP70 promoter in response to 
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TSA.114 In Drosophila, class I/II HDAC inhibitors, TSA and SoBu, also affect the 
chromatin structure at the site where HSP70 gene is located and significantly promote the 
HSP70 gene transcription and hence play important roles in HSP gene regulation.115 
Furthermore, these two inhibitors, TSA and SoBu, promote HSP22 and HSP70 expression 
and extend the lifespan in Drosophila.116 Interestingly, we found TSA to enhance the 
reversibility of tachypacing-induced remodeling in HL-1 cardiomyotes and boost HSP70 
expression (unpublished data). Taken together, these data suggest class I/II HDACs 
negatively regulate HSP production and inhibitors of class I/II HDACs can boost HSP 
production. Notably, the use of broad spectrum inhibitors precludes further identification of 
specific class I/II HDACs that are responsible for HSP induction. However, as the Class II 
HDACs have low activity in vivo, it is conceivable that mainly class I HDACs convey the 
inhibition of HSPs. 
In contrast, a class IIb HDAC, HDAC6, and a class III HDACs, SIRT1, have both been 
implicated in boosting/facilitating the heat shock response (HSR) via regulation of HSF1 in 
cells under proteotoxic stress.  Hsp90-HSF1 complex is present in the unstressed cell in 
cytoplasm and dissociates during stress.117 In stressed cells, HDAC6 senses ubiquitinated 
cellular aggregates via its ubiquitin binding domain and consequently mediates the 
dissociation of the repressive HSP90-HSF1 complex leading to subsequent release and 
activation of HSF1, in turn inducing the expression of major cellular chaperones including 
HSP70 and HSP25.118  Notably,  the ubiquitin binding domain and not the catalytic domain 
of HDAC6 is required for stress-induced HSF1 activation.118 Thus, tubacin, which inhibits 
the HDAC6 activity and conserves microtubule structure in AF20, will not interfere with the 
role of HDAC6 in boosting HSP expression under stress.  Furthermore, a class III HDAC, 
SIRT1, boosts HSP production by deacetylation of HSF1 K80, thereby prolonging HSF1 
binding to the promoter of HSP70 by maintaining HSF1 in a deacetylated, DNA-binding 
competent state. Conversely, down-regulation of SIRT1 accelerates the attenuation of the 
HSR and release of HSF1 from its cognate promoter elements.119 These results provide a 
mechanistic basis for the requirement of HSF1 in the regulation of life span and establish a 
role for SIRT1 in protein homeostasis and the HSR.119   
In summary, HDACs role in the regulation of HSP production is class dependent. The 
deacetylase activity of Class I/IIa HDACs negative regulate HSP expression. Class IIb 
HDAC6 induces HSP expression in the cytoplasm, which is dependent of the ubiquitin 
binding domain. SIRT1 positively regulates HSP expression through its deacetylase 
domain.  One possible explanation of the different actions of class I/II HDACs and SIRT1 
on HSR may constitute of the different substrates they address. Class I/II HDACs, 
especially class I HDACs, deacetylate histones, resulting in chromatin condensation, thus 
rendering the heat shock element (HSE) to become unaccessible for HSF1 to bind the HSE 





























in the promoter sequence of hsp genes. In contrast, the SIRT1 deacetylates HSF1 itself119, 
which increases the affinity of HSF1 to HSE and thus positively regulate HSR. 
2.4. Proteostasis and redox homeostasis:  crosstalk between sirtuins and PARPs via 
NAD+ 
A proper proteostasis requires a well-maintained energy balance, i.e. a proper redox 
homeostasis. Like other cell types, cardiomyocytes encompass the basic features of 
proteostasis, but they are postmitotic, highly specialized, force-generating, beating cells.120 
In terms of proteostasis, there is a permanent turnover of contractile proteins in an 
environment under pressure to maintain the redox homeostasis due to the high number of 
mitochondria, which produce the required ATP energy by redox reactions while generating 
potentially deleterious ROS.121 Nicotinamide adenine dinucleotide (NAD+) is a coenzyme 
and essential in redox reactions producing ATP. Enzymes that consume NAD+ thus 
interfere with ATP production and redox state. 
Interestingly, NAD+ is a rate-limiting co-substrate for the class III HDACs or sirtuins 
(SIRTs 1-7), implying that NAD+ modulation may regulate sirtuin function and, 
consequently, oxidative metabolism. Sirtuins target a wide range of cellular proteins in the 
nucleus, cytoplasm, and mitochondria for post-translational modification by acetylation 
(SIRT1, SIRT2, SIRT3 and SIRT5) or ADP ribosylation (SIRT4 and SIRT 6).122 The 
orthologs of sirtuins in lower organisms play a critical role in regulating lifespan.122  SIRT1 
functions in glucose homeostasis as a modulator of PGC1-α in a NAD+ dependent 
manner.96 It is important to note that although SIRT1 is not itself physically associated with 
mitochondria, it also impacts mitochondrial function.123 The mitochondrial localization of 
SIRT3–5 is especially intriguing, because mitochondrial dysfunction is associated with 
mammalian aging and many diseases, including cardiac diseases, neurodegenerative 
diseases and cancer.124  There is growing evidence linking mitochondrial sirtuins with 
regulating energy equilibrium and mammalian lifespan.125  Very recently, Gupta et al. 
found that activation of mitochondrial SIRT3 by a novel SIRT3 activator, honokiol (HKL), 
blocks and reverses cardiac hypertrophy in mice.126  HKL is present in mitochondria, 
enhances SIRT3 expression nearly twofold and further increase its activity. Increased 
SIRT3 activity is associated with reduced acetylation of mitochondrial SIRT3 substrates, 
MnSOD and oligomycin-sensitivity conferring protein (OSCP). HKL-treatment increases 
mitochondrial rate of oxygen consumption and reduces ROS synthesis in wild type, but not 
in SIRT3-KO cells. Moreover, HKL-treatment blocks cardiac fibroblast proliferation and 
differentiation to myofibroblasts in a SIRT3-dependent manner.126 Thus, NAD+-dependent 
sirtuin activity seems essential in maintaining redox homeostasis and consequently essential 
for proper preoteostasis. 
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Activation of PARP enzymes, a family of major NAD+ consumers, deplete NAD+ 
levels thereby inhibiting sirtuins activity.123 In line with this premise, decreased activity of 
PARP1 increases NAD+ bioavailability, resulting in SIRT1 activation and protection 
against metabolic disease.123 Canto et al. evaluated whether similar effects could be 
achieved by increasing the supply of nicotinamide riboside (NR), a recently described 
natural NAD+ precursor with the ability to increase NAD+ levels. They show that NR 
supplementation in mammalian cells and mouse tissues increases NAD+ levels and 
activates SIRT1 and SIRT3, culminating in enhanced oxidative metabolism and protection 
against high fat diet-induced metabolic abnormalities. Consequently, their results indicate 
that the natural vitamin, NR, could be used as a nutritional supplement to ameliorate 
metabolic and age-related disorders characterized by defective mitochondrial function.127 
Both defective mitochondrial and derailed redox homeostasis is involved in AF.128,129 In 
chapter 5, we show that inhibition of NAD+ depletion caused by tachypacing-induced 
PARP1 activation, resulted in remodeling in experimental models systems for AF. How 
PARP1 activation induces NAD+ depletion and thereby influences sirtuins function, 
downstream energy metabolism and proteostasis in AF remains to be elucidated. 
3. CONCLUSIONS AND FUTHER PERSPECTIVES 
In summary, we discovered several novel key modulators of proteostasis, including 
HDAC6, HDAC5, PARP1 and ER-stress induced autophagy, to be involved in AF 
initiation and progression. Targeting of these modulators with compounds revealed 
protective effects against AF progression in experimental model systems for AF. However, 
it is still an open question how to explain the apparent effectiveness of interventions that 
target only one single factor in these pathways controlling proteostasis. Accumulating 
evidence from our studies suggest that their effectiveness is due to an interplay between 
these factors in the cardiac proteostasis network, which may include the protection of 
shared downstream targets. Studies from cardiac conditions other than AF, such as heart 
failure and hypertrophy, shed additional light on how HDACs regulate proteostasis by 
themselves or by the interplay with other modulators including HSPs, autophagy and 
energy metabolism. The pathways constituting this interplay still remain to be elucidated in 
AF. Furthermore, although we obtained proof of concept that some pharmacological 
interventions directed at these key modulators of proteostasis prevent AF initiation and 
progression, it is unknown whether such interventions can reverse AF structural 
remodeling. Since most AF patients are subjected to cardiomyocyte remodeling at the 
moment they enter a clinic, therapies directed at enhancing the reversibility of 
cardiomyocyte remodeling and thereby improving functional recovery after AF conversion 
are clinically of major importance. 
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